Aptinyx Inc (NASDAQ:APTX) Receives Average Rating of “Buy” from Brokerages

Share on StockTwits

Shares of Aptinyx Inc (NASDAQ:APTX) have received a consensus recommendation of “Buy” from the nine research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $13.67.

APTX has been the topic of a number of research reports. ValuEngine upgraded Aptinyx from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research cut Aptinyx from a “buy” rating to a “hold” rating in a report on Tuesday, October 15th. JPMorgan Chase & Co. cut Aptinyx from a “neutral” rating to an “underweight” rating in a report on Tuesday, August 13th. Finally, Wedbush initiated coverage on Aptinyx in a report on Thursday, September 12th. They issued an “outperform” rating and a $7.00 price target on the stock.

APTX opened at $3.08 on Wednesday. The stock has a market cap of $101.02 million and a P/E ratio of -1.17. The stock’s 50 day simple moving average is $3.49 and its 200 day simple moving average is $3.51. Aptinyx has a 1-year low of $2.61 and a 1-year high of $27.36.

Aptinyx (NASDAQ:APTX) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.36) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.16. The business had revenue of $0.93 million for the quarter, compared to analysts’ expectations of $0.95 million. Aptinyx had a negative return on equity of 40.01% and a negative net margin of 1,504.24%. As a group, equities analysts expect that Aptinyx will post -1.89 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in Aptinyx during the 2nd quarter valued at $49,000. Gabelli Funds LLC grew its holdings in Aptinyx by 45.9% during the 2nd quarter. Gabelli Funds LLC now owns 15,901 shares of the company’s stock valued at $53,000 after buying an additional 5,000 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in Aptinyx during the 2nd quarter valued at $54,000. Weiss Asset Management LP acquired a new stake in Aptinyx during the 2nd quarter valued at $65,000. Finally, A.R.T. Advisors LLC grew its holdings in Aptinyx by 15.9% during the 2nd quarter. A.R.T. Advisors LLC now owns 27,000 shares of the company’s stock valued at $90,000 after buying an additional 3,695 shares during the last quarter. Hedge funds and other institutional investors own 53.09% of the company’s stock.

Aptinyx Company Profile

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

See Also: What is Liquidity?

Analyst Recommendations for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Short Interest in Waterstone Financial, Inc.  Increases By 6.1%
Short Interest in Waterstone Financial, Inc. Increases By 6.1%
Viacom, Inc.  Short Interest Up 7.4% in October
Viacom, Inc. Short Interest Up 7.4% in October
Zynerba Pharmaceuticals Inc  Short Interest Down 10.5% in October
Zynerba Pharmaceuticals Inc Short Interest Down 10.5% in October
FAT Brands  Downgraded to “Hold” at ValuEngine
FAT Brands Downgraded to “Hold” at ValuEngine
Crestwood Equity Partners  Stock Rating Lowered by ValuEngine
Crestwood Equity Partners Stock Rating Lowered by ValuEngine
AGM Group  Stock Rating Upgraded by ValuEngine
AGM Group Stock Rating Upgraded by ValuEngine


© 2006-2019 Ticker Report